1. Home
  2. RNTX vs AURE Comparison

RNTX vs AURE Comparison

Compare RNTX & AURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$0.79

Market Cap

65.3M

Sector

Health Care

ML Signal

HOLD

Logo Prestige Wealth Inc. Class A Ordinary Shares

AURE

Prestige Wealth Inc. Class A Ordinary Shares

HOLD

Current Price

$1.25

Market Cap

65.4M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
RNTX
AURE
Founded
2001
2018
Country
United States
Hong Kong
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
65.3M
65.4M
IPO Year
2017
2019

Fundamental Metrics

Financial Performance
Metric
RNTX
AURE
Price
$0.79
$1.25
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$10.00
N/A
AVG Volume (30 Days)
367.2K
13.6K
Earning Date
05-15-2026
06-01-2026
Dividend Yield
N/A
N/A
EPS Growth
44.16
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.69
$0.18
52 Week High
$2.18
$3.53

Technical Indicators

Market Signals
Indicator
RNTX
AURE
Relative Strength Index (RSI) 51.60 34.55
Support Level $0.71 $0.22
Resistance Level $0.88 $2.67
Average True Range (ATR) 0.06 0.15
MACD 0.00 -0.02
Stochastic Oscillator 41.20 22.41

Price Performance

Historical Comparison
RNTX
AURE

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

About AURE Prestige Wealth Inc. Class A Ordinary Shares

Aurelion Inc is a Tether Gold (XAUT) Real World Asset (RWA) company focused on developing a business around tokenized gold. XAUT combines the stability of physical gold with the efficiency of blockchain, providing investors access to a tokenized gold reserve that could serve as a haven to inflation, currency devaluation, and crypto volatility. In parallel to building a business around the development of tokenized gold, Aurelion provides wealth management and asset management services.

Share on Social Networks: